je.st
news
Home
› Pfizer's RAPAMUNE (sirolimus) Becomes First FDA-Approved Treatment For Lymphangioleiomyomatosis (LAM), A Rare Progressive Lung Disease
Pfizer's RAPAMUNE (sirolimus) Becomes First FDA-Approved Treatment For Lymphangioleiomyomatosis (LAM), A Rare Progressive Lung Disease
2015-06-03 06:19:12| drugdiscoveryonline Home Page
Pfizer Inc. announced recently that the U.S. Food and Drug Administration (FDA) has approved RAPAMUNE (sirolimus) for the treatment of lymphangioleiomyomatosis (LAM), a rare, progressive disease that affects the lungs, kidneys and the lymphatic system
Tags: treatment
disease
rare
progressive
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||